Zurück
Werbung
Immatics schreibt:
"Comprehensive clinical data on ACTengine® IMA203 TCR T-cell therapy were recently published in Nature Medicine. The manuscript includes encouraging results from 40 heavily pretreated patients with solid tumors, including melanoma, mostly treated during the Phase 1a dose escalation part of the trial. "
und weiter
"What’s next for ACTengine® IMA203 TCR T?
- IMA203 is currently being evaluated in, SUPRAME, a randomized-controlled Phase 3 trial in advanced melanoma patients.
- In addition to cutaneous melanoma, Immatics intends to expand the IMA203 TCR-T opportunity to treat uveal melanoma patients and will continue to evaluate IMA203 in this patient population through the ongoing Phase 1b trial.
"
